WuXi STA opens Oligonucleotide and Peptide manufacturing facility
Site Enhances New Modality CRDMO Platform Capacity for Customers
Site Enhances New Modality CRDMO Platform Capacity for Customers
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Subscribe To Our Newsletter & Stay Updated